Back to top
more

SCYNEXIS, Inc. (SCYX)

(Delayed Data from NSDQ)

$6.81 USD

6.81
734,997

+0.66 (10.73%)

Updated Nov 25, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 27% (186 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

Research for SCYX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

INDUSTRY: Medical - Drugs

Reports for Purchase

Showing records 141 - 160 ( 19451 total )

Company: Ocular Therapeutix, Inc.

Industry: Medical - Drugs

Record: 141

11/06/2020

Company Report

Pages: 6

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 142

11/06/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 143

11/06/2020

Company Report

Pages: 6

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Calithera Biosciences, Inc.

Industry: Medical - Drugs

Record: 144

11/06/2020

Company Report

Pages: 7

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 145

11/06/2020

Company Report

Pages: 8

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 146

11/06/2020

Company Report

Pages: 5

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 147

11/06/2020

Company Report

Pages: 6

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Radius Health, Inc.

Industry: Medical - Drugs

Record: 148

11/06/2020

Company Report

Pages: 5

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Flexion Therapeutics, Inc.

Industry: Medical - Drugs

Record: 149

11/06/2020

Company Report

Pages: 7

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 150

11/06/2020

Company Report

Pages: 8

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 151

11/06/2020

Company Report

Pages: 9

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Theravance Biopharma, Inc.

Industry: Medical - Drugs

Record: 152

11/06/2020

Company Report

Pages: 5

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Harpoon Therapeutics, Inc.

Industry: Medical - Drugs

Record: 153

11/06/2020

Daily Note

Pages: 8

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Translate Bio, Inc.

Industry: Medical - Drugs

Record: 154

11/06/2020

Daily Note

Pages: 8

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Entasis Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 155

11/06/2020

Company Report

Pages: 6

3Q20: Pivotal Trials Still Impacted by COVID-19, But This Too Shall Pass

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Translate Bio, Inc.

Industry: Medical - Drugs

Record: 156

11/06/2020

Company Report

Pages: 5

3Q20 - COVID-19 Vaccine Trial Initiation in Humans Delayed

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Entasis Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 157

11/06/2020

Company Report

Pages: 8

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party

Company: Entasis Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 158

11/06/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Ampio Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 159

11/06/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Concert Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 160

11/06/2020

Company Report

Pages: 6

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Available: 12/06/2020

Research Provided by a Third Party